On March 11, Covid-19, a novel coronavirus was declared a pandemic by the WHO, and at the time of writing this manuscript, Covid-19 has infected 3,913,643 people globally with 270,426 deaths.\[[@ref1][@ref2]\] The first case of Covid-19 in India was reported on January 30, 2020, from Kerala, the cases started increasing toward the end of March, and total Covid-19 cases in India have crossed the 50000 mark with over 1800 deaths.\[[@ref3][@ref4]\] \[[Table 1](#T1){ref-type="table"}\].

###### 

Total COVID-19 positive cases reported from India
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Some experts criticized India for testing too less numbers despite the call by the WHO to adopt "test, test, and test" approach.\[[@ref5][@ref6]\] India chose a different approach and went for total lockdown for 1.3 billion people on March 24.\[[@ref6][@ref7]\] This was complemented by the state directions for the compulsory use of face masks by the people when moving outdoors.\[[@ref6]\]

Initial Indian strategy based on the advice of the Indian Council of Medical Research (ICMR) was that of limited testing of people with foreign travel, contacts of Covid-19 patients, and severe acute respiratory illness from all over the country.\[[@ref8]\] This strategy backed by the national lockdown was successful, and India has apparently been able to flatten the curve of Covid-19 infections by extended the doubling rate of Covid-19 infections to 6 days from the earlier predicted time of 3 days in the initial phases.\[[@ref7]\] Indian Health Ministry on 5^th^ of May announced doubling time of 12 days which was later revised to 10.2 days on 7^th^ of May, 2020, which is still much better than most developed countries.\[[@ref9]\] This gave enough time for India to equip its hospitals by training the workforce, procurement, and manufacture of personal protective equipments, drugs, and ventilators for the Covid-19 cases. Meanwhile the developed countries such as the US, Italy, Spain, and the UK that went ahead with an approach of "test, test, and test" and delayed the lockdown resulted in a spike of infections \[[Table 2](#T2){ref-type="table"}\].\[[@ref2]\] Till May 8^th^, India had tested only 984 people per million.\[[@ref2]\] This testing vigor of India is in stark contrast to most other large nations who have tested over 20,000-30,000 people per million \[[Table 2](#T2){ref-type="table"}\].

###### 

Comparative Covid-19 burden and testing vigor of India and other nations

  Country    Cases/1 M Population   Deaths/1 M population   Tests/ 1M population   Test Positivity   Deaths/Cases
  ---------- ---------------------- ----------------------- ---------------------- ----------------- --------------
  Spain      5,494                  558                     41,332                 13%               10%
  USA        3,905                  232                     25,068                 16%               6%
  Italy      3,570                  495                     39,385                 9%                14%
  UK         3,045                  451                     22,605                 13%               15%
  France     2,678                  398                     21,213                 13%               15%
  Germany    2,022                  88                      32,891                 6%                4%
  Israel     1,893                  28                      49,963                 4%                1%
  Iran       1,228                  77                      6,485                  19%               6%
  Russia     1,214                  11                      32,913                 4%                1%
  S. Korea   211                    5                       12,666                 2%                2%
  India      41                     1                       984                    4%                3%

Interestingly, Paul Romer, a Nobel-winning economist, has proposed to test 7% of the population every day and putting them on a rotating schedule every 2 weeks as the only long-term way of keeping the vast majority of people out in normal life.\[[@ref10]\] For the United States, this would mean 150 million tests a week, and for India, this means 650 million tests. This could be one of the reasons that India did not choose the "test, test, and test" pathway proposed by the WHO. The order for 5 lakh rapid diagnostic kits was placed on March 28, by India, but the deadline was reported to have been postponed thrice by 5 days each as China supplied the available kits to the US.\[[@ref11]\] The supply of testing kits to India and other developing countries, therefore, is highly likely to be affected due to the persistent demand and pressure on the suppliers from the US, Italy, France, Spain, Germany, the UK, and other developed nations. Despite all limitations, with 1,357,413 tests, India ranks 8^th^ in the number of tests conducted till date by any country and is bound to surpass other nations in the times to come.\[[@ref2]\]

Given the prevailing circumstances and available infrastructure at the onset of this pandemic, India has done a fairly decent job by keeping Covid-19 in check. Meanwhile, ICMR has steadily increased its testing capacity to match the rising number of cases in India \[[Table 3](#T3){ref-type="table"}\].\[[@ref8]\]

###### 

Growth in the number of COVID-19 testing labs in India
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The WHO has approved the National Institute of Virology (NIV), Pune, as the reference center for confirmation of all Covid-19 cases diagnosed in peripheral laboratories in India.\[[@ref12]\] As of now, all the suspected cases of Covid-19 in India are being tested using the real-time reverse transcriptase-polymerase chain reaction (rRT-PCR). A negative nucleic acid amplification test (NAAT) result, however, does not rule out Covid-19 infection because of poor overall sensitivity, and therefore, few important factors that must be kept in mind while reporting a negative result of NAAT include with following:\[[@ref12]\]

Poor quality of specimen due to variance in the technique of obtaining nasopharyngeal and oropharyngeal swabs resulting in little patient materialImproper handling and shipping of the sampleSpecimens collected late in the convalescenceVirus mutation or PCR inhibition.Less stability of viral genome during the extraction process

Each laboratory in India has a capacity of testing roughly 100 samples per day. In the event of community transmission, this capacity is surely going to become overwhelmed. Foreseeing this eventuality, ICMR has adopted the following strategies to augment the testing capacity of the existing laboratories:

Validation of non-US-FDA/CE-IVD-approved RT PCR kits:\[[@ref8]\] ICMR has validated 28 RT PCR kits, of which 10 were found satisfactory and are approved for use in IndiaAdoption of rapid antibody-based testing for Covid-19 on April 4, 2020:\[[@ref8]\] The advisory is focused on testing in the containment zones and areas with clustering of cases. The rapid antibody tests approved by the US-FDA/CE-IVD or non-CE-IVD or validated by ICMR-NIV with marketing approval by DCGI may be used for the diagnosis of Covid-19So far, 16 antibody-based kits have been evaluated by NIV, of which 8 are approved for use in India.\[[@ref8]\] The latest update of ICMR advises rRT-PCR for influenza-like illness presenting within 7 days and rapid antibody-based tests after 7 days of illness\[[@ref8]\]Advisory on pooling of samples for molecular testing:\[[@ref8]\] On April 13, 2020, ICMR released an advisory regarding the pooling of samples for molecular testing with an objective to increase the testing capacity of laboratories.\[[@ref8]\] This protocol has been validated at the King George\'s Medical University, Lucknow, in IndiaValidation of Truenat™ beta CoV for test on Truenat™ workstation for Covid-19 testing by the ICMR on April 14, 2020:\[[@ref8]\] Truenat™ machines are designed to work on a battery without the need for an air conditioner as is needed for GeneXpert® machines.\[[@ref13]\] They were designed to detect tuberculosis at the primary health-care level. Already, 800 of these machines are installed in various parts of India, half of which are in the government sector.\[[@ref14]\] The cost of Truenat™ workstation is roughly 6000 US\$.\[[@ref15]\] The kits for Turenat™ beta CoV will be supplied with a virus lysis buffer to render the sample non-infective at the bedside. All positive samples will need to be confirmed using rRT-PCR. [Table 4](#T4){ref-type="table"} gives a comparison of available testing options in the near future with their advantages and limitations for Indian laboratories.
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Advantages and limitations of the available testing options in India

  Type of test           Advantages                                                           Limitations
  ---------------------- -------------------------------------------------------------------- ---------------------------------------------------------------
  rRT PCR                High specificity                                                     Varied clinical sensitivity
                                                                                              Need for biosafety level-2 or 3
                                                                                              Full coverall protection required
                                                                                              Limited availability of laboratories and skilled manpower
                                                                                              Costly (Rs. 5000/test)
                                                                                              Takes 5 h
  Antibody based tests   Lower cost (Rs. 2000-3000/test)                                      Low sensitivity in 1^st^ week
                         Rapid (3-15 min)                                                     Limited supply of kits internationally Poor quality of kits
                         Gloves, head cover and mask suffice as protective equipment          
                         Stable at room temperature                                           
  Truenat™ beta CoV      Indian indigenous technology                                         Availability of kits
                         Low cost (Rs. 1000/test)                                             Need confirmatory testing by RT-PCR
                         800 machines installed in India                                      
                         High specificity                                                     
                         The same machine can test TB, HIV                                    
                         No need for Air conditioner                                          
                         Easy to perform in primary care                                      
                         Battery operated and portable                                        
  Pooled PCR             For low prevalence (\<2%) areas                                      Pooling is not recommended at areas with \>5% positivity rate
                         Cost effective for asymptomatic people and pre-operative screening   Not for contacts of Covid-19 patients

Covid: Coronavirus disease, rRT-PCR: Real-time reverse transcriptase-polymerase chain reaction, CoV: Coronavirus, TB: Tuberculosis

Among all the above measures, pooled PCR- and Truenat™-based testing at 400--800 sites seems to be the most promising step at the moment. RDTs also are good in the 2^nd^ week of infection. They should also be used for screening of health-care professionals who may have accidentally got infected resulting in mild symptoms and therefore did not get tested. In the US, a study of 9292 health-care professionals who were Covid-19 positive has shown that 90% did not require hospitalization and 8% did not develop any symptom at all.\[[@ref16]\]

To conclude, India\'s strategic testing approach while ramping up its testing capabilities using innovative methods is helping keep the Covid-19 in check and has been complemented by the prolonged national lockdown and directions for universal use of masks in public places. India is all set to step-up the testing capabilities and to capitalize on the early advantage against Covid-19. This is a challenge that India cannot afford to loose.
